Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Michael J. Fox Foundation

Pfizer Venture Investments

Mission BioCapital

Atlas Venture

Tekla Capital Management

Pivotal bioVenture Partners

Surveyor Capital

Cormorant Asset Management

Eli Lilly

Arkuda Therapeutics

This week at the Alzheimer's Association® International Conference, Arkuda Therapeutics will present preclinical data on lead development candidate ARKD-104, a novel oral therapeutic in development for the treatment of GRN-related frontotemporal dementia. The study showed treatment with ARKD-104 markedly increased progranulin levels – critical to restoring lysosomal function in not only FTD-GRN but in other neurodegenerative diseases. Learn more: https://lnkd.in/enX_JJcg

#progranulin #granulin #lysosome #endFTD #Alzheimers

Congrats to Thomas Kukar's lab (+ Arkuda team members Chris Holler, Ph.D., Bonne Thompson, Giuseppe Astarita, and Jean-François Blain) on this critically important work demonstrating the important role that granulins play in FTD. 

The team at Arkuda Therapeutics continues to advance drug candidates which modulate both progranulin and granulins towards clinical studies, with the goal of someday offering novel treatments for FTD and other neurodegenerative diseases. 

#granulins #ftd #therapeutics #neurodegeneration #neurodegenerativediseases

https://lnkd.in/gmEx-CQb

Congratulations to Raymond Hurst and the rest of the Arkuda Therapeutics team for a great presentation at #adpd2023, "Therapeutic Potential of ARKD-104 for Treatment of Frontotemporal Dementia and Other Neurodegenerative Diseases"

Wishing everyone a happy International Women's Day!

Today and every day we celebrate the incredible achievements of women in different aspects of life all over the world.  We are committed to an inclusive workplace which recognizes the importance of collective activism in driving sustainable change, and aspire towards a world in which we all #EmbraceEquity.

 #IWD2023

Cortexyme is a biopharmaceutical company focused on developing therapeutics for Alzheimer's disease and other degenerative disorders.

Cortexyme

Denali Therapeutics is a biotechnology company focused on discovering and developing therapies for neurodegenerative diseases.

Denali Therapeutics

Alector is a biotechnology company that focuses on developing therapies for neurodegenerative disorders by targeting the immune system.

Alector

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Their lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 7, 2024 4:30 PM	9409d389
translate crunchbase fundingrounds	general
peers	general	Feb 7, 2024 4:30 PM	e4748aaf
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ARKUDATX

Arkuda Therapeutics